The article discusses several recent clinical trials in noncolorectal gastrointestinal cancer. Here’s a summary of the key trials mentioned:
Advanced Hepatocellular Carcinoma Trial: This randomized placebo-controlled phase 2/3 study by the National Cancer Institute (NCI) is evaluating the effectiveness of a device called TheraBionic in treating advanced hepatocellular carcinoma. TheraBionic uses low levels of radiofrequency electromagnetic fields, delivered through a spoon-shaped antenna held in the patient’s mouth. The trial, which started recruitment in July 2023, aims to determine if this treatment can improve survival and quality of life in patients.
Advanced Biliary-Tract Cancers Trial: An open-label, phase 3 trial is exploring the efficacy of the immunotherapy drug durvalumab (Imfinzi) in combination with standard gemcitabine-based chemotherapy for adults with advanced biliary-tract cancers. The trial, which began in August 2023, is assessing the tolerability of this combination therapy and its impact on survival and quality of life.
Primary Biliary Cholangitis and Compensated Cirrhosis Trial: This randomized, double-blind, placebo-controlled phase 3 study is investigating whether seladelpar, an experimental oral therapy, can delay death, liver transplantation, and other progression markers in adult patients with primary biliary cholangitis and compensated cirrhosis. Seladelpar selectively inhibits peroxisome proliferator-activated receptor delta, a regulator of disease-related metabolic pathways.
These trials represent significant steps in advancing treatment options for various gastrointestinal cancers, potentially offering new hope for patients with these conditions.